Plenary Session 1 (Day 1)
Targeted protein degradation as a therapeutic modality in cancer
Chaired by Dr Olivia Rossanese, Head of the Division of Cancer Therapeutics and Director of the Centre for Cancer Drug Discovery
Improving PROTAC selectivity by a Degron Blocking strategy
Dr John Caldwell, Senior Staff Scientist in the Targeted Protein Degradation Group led by Professor Zoran Rankovic in the Division of Cancer Therapeutics
Targeting BCL6: a monovalent degrader approach
Dr Alice Harnden, Senior Scientific Officer in the Medicinal Chemistry 4 (including Analytical Chemistry) Group led by Professor Swen Hoelder in the Division of Cancer Therapeutics
From idea to project: Inducing immunogenic cell death by degradation of RIPK1
Dr Benjamin Bellenie, Senior Staff Scientist in the Medicinal Chemistry 4 (including Analytical Chemistry) Group led by Professor Swen Hoelder in the Division of Cancer Therapeutics